Comment on "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies"

Pharmacol Res. 2021 Oct:172:105862. doi: 10.1016/j.phrs.2021.105862. Epub 2021 Sep 1.

Authors

Mei Qiu¹, Xu-Bin Wei², Wei Wei³

Affiliations

¹ Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen 518110, China. Electronic address: 13798214835@sina.cn.
² Department of Cardiology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China.
³ Department of Pharmacy, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China.

PMID: 34481073
DOI: 10.1016/j.phrs.2021.105862

No abstract available

Keywords: Cardiovascular; Death; GLP1RA; SGLT2i; Type 2 diabetes.

Publication types

Letter
Comment

MeSH terms

Cardiovascular System* / drug effects
Humans
Hypoglycemic Agents
Retrospective Studies
Sodium-Glucose Transporter 2 Inhibitors* / pharmacology

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors